Company
Immuno Cure Holding (HK) Limited is a biotechnology group focusing on its patented technology platforms for researching and developing of immunotherapy for cancers, inflammatory and infectious diseases. The patented technology platforms consist of a PD-1 based DNA vaccine technology platform aimed at targeting various infectious diseases and cancers, alongside an anti-PD-1 isoform antibody to suppress inflammation.
The Group is headquartered in Hong Kong Science Park and Shenzhen. It boasts an experienced management team and a group of partners with expertise in the DNA vaccine ecosystem, including R&D institutions, CDMO, electroporation device technology, DNA vaccine manufacturing process technology, CRO and GMP manufacturers.
Utilizing the two technology platforms, the Group has developed a list of pipelines for HIV and cancer treatments as well as COVID-19 prevention.
